|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
US12702658B2
(en)
|
2020-04-24 |
2026-08-11 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
WO2022109487A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
CN116867792A
(zh)
*
|
2021-02-09 |
2023-10-10 |
基因泰克公司 |
四环氧氮杂䓬化合物及其用途
|
|
CN117043167A
(zh)
|
2021-03-17 |
2023-11-10 |
劲方医药科技(上海)有限公司 |
嘧啶并环类化合物及其制法和用途
|
|
MX2023015533A
(es)
*
|
2021-06-21 |
2024-01-23 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
|
|
TW202315626A
(zh)
*
|
2021-08-31 |
2023-04-16 |
大陸商勁方醫藥科技(上海)有限公司 |
嘧啶并環類化合物及其製法和用途
|
|
JP2025504041A
(ja)
*
|
2022-01-30 |
2025-02-06 |
シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド |
キノリン系化合物及びその使用
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
EP4511127A1
(en)
*
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2023265688A1
(en)
|
2022-05-06 |
2024-10-17 |
PAQ Therapeutics Inc. |
Kras g12d proteolysis targeting chimeras
|
|
CN119365467A
(zh)
*
|
2022-05-19 |
2025-01-24 |
基因泰克公司 |
氮杂-四环氧氮杂䓬化合物及其用途
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
TW202409051A
(zh)
*
|
2022-07-27 |
2024-03-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠環類化合物、其製備方法及其在醫藥上的應用
|
|
KR20250037564A
(ko)
*
|
2022-07-29 |
2025-03-17 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Kras g12d 억제제를 포함하는 약학적 조성물
|
|
AU2023320565A1
(en)
|
2022-08-05 |
2025-01-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2024032704A1
(en)
*
|
2022-08-11 |
2024-02-15 |
Beigene, Ltd. |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
WO2024041573A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Zai Lab (Shanghai) Co., Ltd. |
Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
|
|
WO2024051721A1
(en)
*
|
2022-09-07 |
2024-03-14 |
Nikang Therapeutics, Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
TW202426459A
(zh)
*
|
2022-09-23 |
2024-07-01 |
大陸商勁方醫藥科技(上海)有限公司 |
嘧啶并環類化合物及其製法和用途
|
|
TW202440594A
(zh)
*
|
2022-12-07 |
2024-10-16 |
大陸商北京加科思新藥研發有限公司 |
稠環化合物及其用途
|
|
TW202430184A
(zh)
*
|
2022-12-20 |
2024-08-01 |
大陸商江蘇恒瑞醫藥股份有限公司 |
Kras g12d抑制劑的結晶形式及製備方法
|
|
CN122187841A
(zh)
*
|
2023-01-18 |
2026-06-12 |
苏州赞荣医药科技有限公司 |
Kras g12d抑制剂和其用途
|
|
WO2024234360A1
(en)
*
|
2023-05-18 |
2024-11-21 |
Nikang Therapeutics , Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
WO2024159471A1
(en)
*
|
2023-02-02 |
2024-08-08 |
Nikang Therapeutics , Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
WO2024159470A1
(en)
*
|
2023-02-02 |
2024-08-08 |
Nikang Therapeutics , Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
WO2024160225A1
(en)
*
|
2023-02-02 |
2024-08-08 |
Nikang Therapeutics, Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
EP4680609A1
(en)
|
2023-03-15 |
2026-01-21 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2024197503A1
(en)
*
|
2023-03-27 |
2024-10-03 |
Nikang Therapeutics , Inc. |
Tricyclic derivatives as kras inhibitors
|
|
CN121487738A
(zh)
|
2023-03-30 |
2026-02-06 |
锐新医药公司 |
诱导ras gtp水解的组合物和其用途
|
|
WO2024208305A1
(zh)
*
|
2023-04-07 |
2024-10-10 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
CN121487951A
(zh)
|
2023-04-07 |
2026-02-06 |
锐新医药公司 |
大环ras抑制剂
|
|
WO2024213979A1
(en)
*
|
2023-04-10 |
2024-10-17 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
WO2024215754A1
(en)
*
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
EP4695261A1
(en)
|
2023-04-14 |
2026-02-18 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024251341A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
WO2024218686A1
(en)
*
|
2023-04-20 |
2024-10-24 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
WO2024230707A1
(zh)
*
|
2023-05-07 |
2024-11-14 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
EP4716531A2
(en)
*
|
2023-05-22 |
2026-04-01 |
Board of Regents, The University of Texas System |
Heterocyclic compounds as nras inhibitors
|
|
WO2025016899A1
(en)
|
2023-07-19 |
2025-01-23 |
Bayer Aktiengesellschaft |
Spirocyclic compounds for the treatment of cancer
|
|
WO2025026903A1
(en)
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
EP4766713A2
(en)
*
|
2023-08-25 |
2026-07-01 |
Ensem Therapeutics, Inc. |
TETRACYCLIC DERIVATIVES, COMPOSITIONS AND ASSOCIATED PROCESSES
|
|
WO2025045141A1
(en)
*
|
2023-08-31 |
2025-03-06 |
Suzhou Zanrong Pharma Limited |
Kras inhibitors and uses thereof
|
|
EP4774280A1
(en)
*
|
2023-09-08 |
2026-07-15 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
*
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025059040A1
(en)
*
|
2023-09-11 |
2025-03-20 |
Newave Pharmaceutical Inc. |
Mutant kras modulators and uses thereof
|
|
KR20260087586A
(ko)
|
2023-10-03 |
2026-06-11 |
피에이큐 테라퓨틱스 인코포레이티드 |
Kras 단백질분해 표적화 키메라
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
KR20260110993A
(ko)
|
2023-10-09 |
2026-07-14 |
인사이트 코포레이션 |
Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR20260096846A
(ko)
|
2023-10-20 |
2026-06-24 |
머크 샤프 앤드 돔 엘엘씨 |
Kras 단백질의 소분자 억제제
|
|
TW202540122A
(zh)
*
|
2023-11-22 |
2025-10-16 |
美商建南德克公司 |
Ｋｒａｓ－ｇ１２ｄ之氮雜－四環氧氮呯抑制劑的多晶型物及合成方法
|
|
WO2025111582A1
(en)
*
|
2023-11-22 |
2025-05-30 |
Genentech, Inc. |
Aza-tetracyclic oxazepine inhibitors of kras-g12d
|
|
WO2025123318A1
(en)
*
|
2023-12-15 |
2025-06-19 |
Shanghai Blueray Biopharma Co., Ltd. |
TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS
|
|
WO2025146194A1
(en)
*
|
2024-01-05 |
2025-07-10 |
Jacobio Pharmaceuticals Co., Ltd. |
Fused tetracyclic compounds and use thereof
|
|
AU2025209726A1
(en)
*
|
2024-01-17 |
2026-07-09 |
Suzhou Zanrong Pharma Limited |
Kras inhibitors and uses thereof
|
|
CN119684315B
(zh)
*
|
2024-01-26 |
2026-05-12 |
苏州盛迪亚生物医药有限公司 |
一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025194134A1
(en)
*
|
2024-03-15 |
2025-09-18 |
Genentech, Inc. |
Linearly substituted oxazepin-5-one kras-g12d inhibitors
|
|
WO2025217319A1
(en)
*
|
2024-04-09 |
2025-10-16 |
Kestrel Therapeutics Inc. |
Ras inhibitors and methods of use thereof
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
TW202615038A
(zh)
|
2024-08-07 |
2026-04-16 |
美商太斯萊特醫藥美國有限責任公司 |
包含拓樸異構酶有效載荷之靶向ｋｒａｓ之共價誘導之藥物結合物
|
|
WO2026039659A1
(en)
*
|
2024-08-14 |
2026-02-19 |
Board Of Regents, The University Of Texas System |
Heterocyclic compounds as ras inhibitors
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026072560A1
(en)
*
|
2024-09-30 |
2026-04-02 |
Ensem Therapeutics, Inc. |
Tetracyclic derivatives, compositions and methods thereof
|
|
WO2026080226A1
(en)
*
|
2024-10-08 |
2026-04-16 |
Ensem Therapeutics, Inc. |
Tricyclic derivatives, compositions and methods thereof
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090333A1
(en)
|
2024-10-23 |
2026-04-30 |
Incyte Corporation |
Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
|
|
US20260137674A1
(en)
|
2024-10-23 |
2026-05-21 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112187A1
(en)
*
|
2024-11-20 |
2026-05-28 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026158694A1
(zh)
*
|
2025-01-27 |
2026-07-30 |
江苏亚虹医药科技股份有限公司 |
Cdk抑制剂及其制备方法和用途
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|